Top Suppliers:I want be here


158966-92-8

158966-92-8 structure
158966-92-8 structure
  • Name: Montelukast
  • Chemical Name: montelukast
  • CAS Number: 158966-92-8
  • Molecular Formula: C35H36ClNO3S
  • Molecular Weight: 586.183
  • Catalog: API Respiratory medication Asthma
  • Create Date: 2018-02-21 08:00:00
  • Modify Date: 2026-07-01 09:37:19
  • Montelukast is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].

Name montelukast
Synonyms Montelukast D6 sodium salt (Rac)
[3H]-Montelukast
(1-{1-{3(R)-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-propylsulfanylmethyl}-cyclopropyl)-acetic acid
Montelukast AcidQ: What is Montelukast Acid Q: What is the CAS Number of Montelukast Acid Q: What is the storage condition of Montelukast Acid Q: What e the applications of Montelukast Acid
Cyclopropaneaceticacid,1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-Methylethyl)phenyl]propyl]thio]Methyl]
Monteluk
Montelukast [INN:BAN]
MFCD05662278
(r-(e))-1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
{1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid
Singul
[14C]-Montelukast
Montelukast free acid
UNII-MHM278SD3E
Brondilat (TN)
Montelukast //BP
Montelukast (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2- (1-hydroxy-1- methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
{1-[({(1R)-1-{3-[(E)-2-(7-Chloroquinolin-2-yl)vinyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid
Montelukast for System Suitability RS
Montelukast - Bio-X
Montair
2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
Montelukas
Montelukast API (Sodium salt)
Singular
[R-(E)]-1-[[[1-[3-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic Acid
2-[1-[[(1r)-1-[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
{1-[({(1R)-1-{3-[(E)-2-(7-Chloro-2-quinolinyl)vinyl]phenyl}-3-[2-(2-hydroxy-2-propanyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid
Montelukastl
Montelukast (INN)
Montelukast Acid
Montelukast(Form A)
Montelukast Sodium- IP/BP
(R,E)-2-[1-[[[1-[3-[2-(7-Chloro-2-quinolyl)vinyl]phenyl]-3-[2-(2-hydroxy-2-propyl)phenyl]propyl]thio]methyl]cyclopropyl]acetic Acid
Description Montelukast is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage[1].
Related Catalog
Target

CysLT1

In Vitro Montelukast (5 μM; 1 h) inhibits APAP-induced cell damage[1].
In Vivo Montelukast (3 mg/kg; oral gavage) protects against APAP-induced hepatotoxicity in mice[1]. Montelukast (1 mg/kg; miniosmotic pump administration) reduces the airway remodeling changes observed in OVA-treated mice and blocks the actions of cysteinyl leukotrienes (LT) C4, D4, and E4 mediated by the CysLT1 receptor[2]. Montelukast (1 mg/kg; miniosmotic pump administration) reduces the elevated levels of IL-4 and IL-13 found in the BAL fluid of OVA-treated mice[2]. Animal Model: C57BL/6J mice (8-week-old; 22-25 g) are induced acute hepatic injury[1] Dosage: 3 mg/kg Administration: Oral gavage 1 h after saline or APAP administration Result: Decreased serum levels of alanine transaminase (ALT) and aspartate aminotransferase (AST), and alleviated liver damage.
References

[1]. Pu S, et, al. Montelukast Prevents Mice Against Acetaminophen-Induced Liver Injury. Front Pharmacol. 2019 Sep 18; 10:1070.

[2]. William RHJ, et, al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002 Jan 1; 165(1): 108-16.

Density 1.3±0.1 g/cm3
Boiling Point 750.5±60.0 °C at 760 mmHg
Molecular Formula C35H36ClNO3S
Molecular Weight 586.183
Flash Point 407.7±32.9 °C
Exact Mass 585.210449
PSA 95.72000
LogP 7.80
Vapour Pressure 0.0±2.6 mmHg at 25°C
Index of Refraction 1.678
Storage condition 2-8°C
Hazard Codes Xi
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.